Published in Klin Wochenschr on July 15, 1982
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
Once versus thrice daily gentamicin in patients with serious infections. Lancet (1993) 4.92
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet (1988) 2.67
Microparticles in cardiovascular diseases. Cardiovasc Res (2003) 2.62
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood (2000) 2.51
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost (2012) 2.39
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost (2001) 2.38
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Meta-analysis: the final answer, or even more confusion? Lancet (1996) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost (2010) 2.19
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost (1999) 2.18
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
[Atherosclerosis partly due to local vasculitis]. Ned Tijdschr Geneeskd (1994) 2.05
[Excess mortality in critically ill patients after treatment with human albumin]. Ned Tijdschr Geneeskd (1998) 2.04
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
[Optimal treatment with oral anticoagulants]. Ned Tijdschr Geneeskd (1996) 2.03
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00
Deep-vein thrombosis. Lancet (1999) 1.98
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making (1997) 1.96
Compression ultrasonography of the leg veins in patients with clinically suspected pulmonary embolism: is a more extensive assessment of compressibility useful? Thromb Haemost (2000) 1.95
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost (2014) 1.90
Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation (1995) 1.82
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation (1992) 1.78
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest (2004) 1.74
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis (1992) 1.73
Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost (2000) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med (2001) 1.72
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 1.70
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost (2005) 1.70
Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost (2006) 1.69
Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med (1983) 1.69
Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr (2001) 1.68
Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation (1997) 1.67
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost (2001) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med (1999) 1.64
Thyroid diseases and cerebrovascular disease. Stroke (2005) 1.63
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J (2001) 1.62
Reliable rapid blood test for the exclusion of venous thromboembolism in symptomatic outpatients. Thromb Haemost (1996) 1.61
The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med (1993) 1.61
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol (1999) 1.60
Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost (1999) 1.60
Intestinal endotoxemia. Clinical significance. Gastroenterology (1988) 1.59
Simultaneous activation of NADPH oxidase-related proton and electron currents in human neutrophils. Proc Natl Acad Sci U S A (2000) 1.58
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost (1997) 1.56
Antigen biological activity ratio for factor VIII in late pregnancy. Lancet (1973) 1.54
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med (1997) 1.54
Family history and inherited thrombophilia. J Thromb Haemost (2006) 1.52
Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost (2009) 1.52
Review: infectious diseases and coagulation disorders. J Infect Dis (1999) 1.50
Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost (2005) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50